uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted December 08, 2017

Limbrel Capsules for Osteoarthritis Linked With Potentially Life-Threatening Health Risk, FDA Warns

On December 4, 2017, the FDA urged consumers not to take Limbrel (Primus Pharmaceuticals), a capsule marketed to manage the metabolic processes associated with osteoarthritis, because it has been associated with serious adverse events, including drug-induced liver injury and a lung condition called hypersensitivity pneumonitis. The FDA recommended Primus Pharmaceuticals recall Limbrel, but the company has not recalled the product at this time. 

Join today to unlock all member benefits including full access to all recalls & warnings

Join Now

Join now at